Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Open access
O’Donnell, Max R., Grinsztejn, Beatriz, Cummings, Matthew J., Justman, Jessica E., Lamb, Matthew R., Eckhardt, Christina M., Philip, Neena M., Cheung, Ying Kuen, Gupta, Vinay, João, Esau, Pilotto, Jose Henrique, Diniz, Maria Pia, Cardoso, Sandra Wagner, Abrams, Darryl, Rajagopalan, Kartik N., Borden, Sarah E., Wolf, Allison, Sidi, Leon Claude, Vizzoni, Alexandre, Veloso, Valdilea G., Bitan, Zachary C., Scotto, Dawn E., Meyer, Benjamin J., Jacobson, Samuel D., Kantor, Alex, Mishra, Nischay, Chauhan, Lokendra V., Stone, Elizabeth F., Dei Zotti, Flavia, La Carpia, Francesca, Hudson, Krystalyn E., Ferrara, Stephen A., Schwartz, Joseph, Stotler, Brie A., Lin, Wen-Hsuan W., Wontakal, Sandeep N., Shaz, Beth, Briese, Thomas, Hod, Eldad A., Spitalnik, Steven L., Eisenberger, Andrew, Lipkin, Walter I. · 2021 · Journal of Clinical Investigation

Abstract

Abstract Background Although convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited. Objective To evaluate the clinical efficacy and safety of convalescent plasma among adults hospitalized with severe and critical COVID-19. Design Randomized, double-blind, controlled, multicenter, phase 2 trial conducted from April 21 st to November 27 th , 2020. Setting Five hospitals in New York City (NY, USA) and Rio de Janeiro (Brazil). Participants Hospitalized patients aged ≥18 years with laboratory-confirmed COVID-19, infiltrates on chest imaging and oxygen saturation ≤ 94% on room air or requirement for supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. Intervention Participants were randomized 2:1 to a single transfusion of either 1 unit of convalescent or normal control plasma. Measurements The primary outcome was clinical status at 28 days, measured using an ordinal scale and analyzed using a proportional odds model in the intention-to-treat population. Results Of 223 participants enrolled, 150 were randomized to receive convalescent plasma and 73 to normal control plasma. At 28 days, no significant improvement in clinical status was observed in participants randomized to convalescent plasma (with an odds ratio (OR) of a 1-point improvement in the scale: 1.50, 95% confidence interval (CI) 0.83-2.68, p=0.180). However, 28-day mortality was significantly lower in participants randomized to convalescent plasma versus control plasma (19/150 [12.6%] versus 18/73 [24.6%], OR 0.44, 95% CI 0.22-0.91, p=0.034). The median titer of anti-SARS-CoV-2 neutralizing antibody in infused convalescent plasma units was 1:160 (IQR 1:80-1:320). In a subset of nasopharyngeal swab samples (n=40) from Brazil that underwent genomic sequencing, no evidence of neutralization-escape mutants was detected. Serious adverse events occurred in 39/147 (27%) participants who received convalescent plasma and 26/72 (36%) participants who received control plasma. Limitations Some participants did not receive high-titer convalescent plasma. Conclusion In adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in 28 days clinical status. The significant reduction in mortality associated with convalescent plasma, however, may warrant further evaluation. Registration ClinicalTrials.gov, NCT04359810 Funding Amazon Foundation Clinical Trial Registration ClinicalTrials.gov Identifier: NCT04359810

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci150646

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 179

Metadata

Authors
O’Donnell, M. R., Grinsztejn, B., Cummings, M. J., Justman, J. E., Lamb, M. R., Eckhardt, C. M., Philip, N. M., Cheung, Y. K., Gupta, V., João, E., Pilotto, J. H., Diniz, M. P., Cardoso, S. W., Abrams, D., Rajagopalan, K. N., Borden, S. E., Wolf, A., Sidi, L. C., Vizzoni, A., Veloso, V. G., Bitan, Z. C., Scotto, D. E., Meyer, B. J., Jacobson, S. D., Kantor, A., Mishra, N., Chauhan, L. V., Stone, E. F., Dei Zotti, F., La Carpia, F., Hudson, K. E., Ferrara, S. A., Schwartz, J., Stotler, B. A., Lin, W.-H. W., Wontakal, S. N., Shaz, B., Briese, T., Hod, E. A., Spitalnik, S. L., Eisenberger, A., & Lipkin, W. I.
Venue
Journal of Clinical Investigation
Published
2021-07-01
Volume
131
Issue
13
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3163808478
Cited by
179
References
3
FWCI
12.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. https://app.cochat.ai/papers/10.1172/jci150646
The paper
O’Donnell, M. R., Grinsztejn, B., Cummings, M. J., Justman, J. E., Lamb, M. R., Eckhardt, C. M., Philip, N. M., Cheung, Y. K., Gupta, V., João, E., Pilotto, J. H., Diniz, M. P., Cardoso, S. W., Abrams, D., Rajagopalan, K. N., Borden, S. E., Wolf, A., Sidi, L. C., Vizzoni, A., . . . Lipkin, W. I. (2021). A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation. https://doi.org/10.1172/jci150646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.